Circulating Tumor Cells with Aberrant ALK Copy Number Predict Progression-Free Survival during Crizotinib Treatment in ALK-Rearranged Non-Small Cell Lung Cancer Patients

导出原文传递

翻译打印收藏纠错

作者： Pailler, Emma ^[1] ; Oulhen, Marianne ^[2] ; Borget, Isabelle ^[3] ; Remon, Jordi ^[4] ; Ross, Kirsty ^[5] ; Auger, Nathalie ; Billiot, Fanny ; Camus, Maud Ngo ; Commo, Frederic ; Lindsay, Colin R. ; Planchard, David ; Soria, Jean-Charles ; Besse, Benjamin ; Farace, Francoise

作者单位： Univ Paris Saclay, Dept Biostat & Epidemiol, Villejuif, France ^[1] Univ Paris Saclay, Circulating Tumor Cells Translat Platform, CNRS, UMS3655,INSERM,US23,AMMICA ^[2] Univ Paris Saclay, Dept Med, Villejuif, France ^[3] Univ Paris Saclay, Dept Biopathol, Villejuif, France ^[4] INSERM, Identificat Mol Predictors & New Targets Canc Tre, Villejuif, France ^[5]

发布时间 2018-01-11

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Cancer research

2017年77卷9期

2222-2230页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Circulating Tumor Cells with Aberrant ALK Copy Number Predict Progression-Free Survival during Crizotinib Treatment in ALK-Rearranged Non-Small Cell Lung Cancer Patients

Cancer research

相似文献

Cancer research

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Circulating Tumor Cells with Aberrant ALK Copy Number Predict Progression-Free Survival during Crizotinib Treatment in ALK-Rearranged Non-Small Cell Lung Cancer Patients

Cancer research

相似文献

Cancer research

相关期刊

检索历史清除